The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Steve Curd appointed as CEO of Wanda

9 Sep 2015 13:00

RNS Number : 5652Y
NetScientific PLC
09 September 2015
 

 

NetScientific plc

 

 

NetScientific announces the key appointment of Steve Curd as CEO of Wanda, Inc.

 

London, UK - 9 September 2015 - NetScientific plc ("NetScientific" or the "Group", AIM: NSCI), the transatlantic biomedical and healthcare technology group, announces the appointment of Steve Curd as CEO of its portfolio company, Wanda, and head of the Group's Digital Health franchise, of which Wanda is the key asset.

Wanda helps healthcare providers improve outpatient care while reducing the costs associated with managing chronic diseases. The company provides a cloud based patient management solution combining comprehensive data-mining and advanced analytics to give clinicians a complete view of their outpatients' current and trending health. Its first medical product is Wanda™ CHF, a clinical decision support system for remotely managing patients with Congestive Heart Failure to help prevent hospital readmissions.

Steve Curd will join the Group on 14th September 2015 to oversee the growth and delivery of its digital health portfolio. He has more than 20 years' experience in driving growth for digital healthcare, commercialising products and delivering exits. Steve has helped secure 15 M&A transactions and numerous successful exits for Digital Health companies. Most recently, Steve was the COO of NantHealth, a healthcare company converging biomolecular medicine and bioinformatics with technology services, where he was responsible for advancing its product portfolio, driving improvements in efficiency and improving client satisfaction. Prior to that, he was CEO at CareInSync, an innovative mobile care coordination platform start-up where he grew the team, refined the business model and improved sales. Other notable positions include CIO at UnitedHealth Group, COO at WebMD, and CEO at VantageMed.

Francois Martelet, Group CEO of NetScientific, commented: "I am delighted to welcome a leader of Steve's calibre to the Group to drive the commercialisation programme for Wanda, our game-changing clinical decision support system. Steve is highly regarded in this area and will play a key role in accelerating the growth of our digital health portfolio, one of our three areas of strategic focus together with diagnostics and therapeutics."

Steve Curd commented: "Wanda represents the next generation of digital health solutions for patient care and I'm excited about the opportunity to drive its commercialisation phase. I look forward to working with NetScientific's diverse mix of digital health companies as its technologies have a real potential to become first or best in class technologies that could improve the lives of millions of people living with chronic diseases."

- Ends -

About NetScientific

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.

For more information, please visit the website at www.netscientific.net. 

 

About Wanda Health

Wanda Health (Wanda, Inc.) is developing cloud-based analytics, as part of a total patient management solution, in partnership with other healthcare providers. The core analytics engine is based on 12 years of research at the Wireless Health Institute at UCLA. Wanda Health has completed development of a predictive analytics engine for use in remotely monitoring patients with Congestive Heart Failure, the leading cause of hospital re-admissions in USA.

 

Contact Details

NetScientific

Peter Thoms, CFO

Tel: +44 (0)77 2055 5752

Investec

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

Instinctif Partners

Melanie Toyne-Sewell / Jayne Crook

Tel: +44 (0)20 7457 2020 Email: netscientific@instinctif.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSSLFFUFISELU
Date   Source Headline
10th May 20249:12 amRNSPDS Biotech: Clinical trial meets study endpoints
15th Apr 20247:00 amRNSProAxsis secures c.£1.8mn investment
27th Mar 20241:34 pmRNSPDS Strategy Update and 2023 Financial Results
13th Mar 20247:00 amRNSBusiness Update
5th Feb 20247:00 amRNSExercise of Options and Issue of Shares
23rd Jan 20247:00 amRNSGlycotest secures $1 million investment
1st Dec 20237:00 amRNSDeepTech Recycling secures £1 million investment
14th Nov 20234:39 pmRNSPDS BioTechnology: Third Quarter Results
13th Nov 20237:00 amRNSDirector/PDMR Shareholding
9th Nov 20235:28 pmRNSPDS Biotech Announces Updated Survival Data
6th Nov 20237:00 amRNSVentive secures c.£900,000 investment
2nd Nov 20237:00 amRNSChange of Adviser
23rd Oct 20236:22 pmRNSPDS Preliminary Biomarker Study Results
13th Oct 20237:00 amRNSExercise of Options
3rd Oct 20234:12 pmRNSDirector/PDMR Shareholding
3rd Oct 20233:21 pmRNSPDS: Interim 24-month survival rate of 74% update
3rd Oct 20237:00 amRNSPDS Biotech: new data on PDS0101
28th Sep 20237:00 amRNSInterim Results
13th Sep 20237:00 amRNSQ-Bot: £3.5 million investment to drive expansion
14th Aug 20235:55 pmRNSPDS Biotech: 2nd Quarter Results, Business Update
14th Aug 20235:51 pmRNSPDS Biotech: Submission of Phase 3 Protocol to FDA
3rd Jul 20237:00 amRNSGrant of Options, Issue of Shares, Director/PDMR
30th Jun 20237:00 amRNSDName-iT Holdings Limited Fundraising
29th Jun 202311:04 amRNSResult of AGM & Board Changes
22nd Jun 20237:00 amRNSVortex Fundraising
14th Jun 20233:31 pmRNSPDS Announces Achievement of Efficacy Threshold
7th Jun 20237:00 amRNSDirector/PDMR Shareholding
6th Jun 20237:00 amRNSNotice of AGM
31st May 20237:01 amRNSPreliminary Results for the year ended 31 Dec 2022
31st May 20237:00 amRNSBoard Changes
26th May 20239:39 amRNSPDS Biotech Announces Interim Data
24th May 20237:00 amRNSSofant and Inmarsat announce joint development
15th May 20233:16 pmRNSPDS Business Update and First Quarter Results
2nd May 20237:00 amRNSGlycotest, Inc. Fundraising
3rd Apr 20237:00 amRNSBusiness Update
30th Mar 20233:51 pmRNSPDS Update
28th Mar 20233:50 pmRNSPDS Business Update and 2022 Financial Results
28th Feb 20237:00 amRNSRelated party loan to ProAxsis Limited
27th Feb 20233:28 pmRNSPDS completes FDA meeting for triple combination
10th Feb 20232:05 pmRNSSecond Price Monitoring Extn
10th Feb 20232:00 pmRNSPrice Monitoring Extension
10th Feb 202311:05 amRNSSecond Price Monitoring Extn
10th Feb 202311:00 amRNSPrice Monitoring Extension
1st Feb 20237:00 amRNSBoard Change
3rd Jan 20231:31 pmRNSPDS Announces Exclusive Global License Agreement
28th Dec 20223:05 pmRNSPDS Biotech: Median Overall Survival announcement
16th Dec 20227:00 amRNSPDS: HPV16 Head and Neck Cancer announcement
12th Dec 20222:00 pmRNSBoard Changes; Options; Co-Investment Agreement
29th Nov 20227:00 amRNSEMV C leads £4.2m round in 5G and SATCOM leader
14th Nov 20222:50 pmRNSPDS Q3 Results and Business Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.